Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,060
- Phase 1794
- Phase 1/Phase 2441
- Phase 3435
- Phase 4233
- Phase 2/Phase 399
Top conditions
- Multiple Sclerosis330
- Multiple Myeloma328
- Asthma194
- Lymphoma179
- Type 1 Diabetes132
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Acute Lymphoblastic Leukemia118
- HIV Infections105
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center49
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California498
- Maryland198
- Alabama178
- Florida151
- Arizona150
- Massachusetts118
- New York114
- Texas112
- Illinois84
- Colorado81
Recruiting studies6,067 total
- NCT05934305Recruiting
Help for shame and stigma in HIV and substance use
This study tests whether a program can reduce shame and stigma for people living with HIV who also have a substance use disorder. It may help you feel less judged and cope better, while supporting HIV care.
Miami, FloridaAges 18 years+ - NCT05923970Recruiting
MMRV vaccine booster in pregnant adults in Alberta
This study looks at whether getting a third dose of the MMRV vaccine during pregnancy is helpful. It focuses on pregnant women who were screened for rubella immunity during routine prenatal testing.
Edmonton, AlbertaAges 18 years+ - NCT05934188Recruiting
Study how gut signals relate to brain aging and diseases
This study looks at how the gut may influence the brain in normal aging and conditions like Alzheimer’s, Parkinson’s, and multiple sclerosis. It may help researchers understand new ways to measure or treat these brain changes over time.
Venice-Lido, VeniceAges 20–90 - NCT05922501RecruitingPhase 2
Test four medicines for relapsed multiple myeloma
This Phase 2 study tests a combination of medicines (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) for multiple myeloma that has come back or did not respond to prior treatment. It may help by better controlling the myeloma after standard therapies have failed.
Boston, MassachusettsAges 18 years+ - NCT05025774Recruiting
Exercise program study for young heart, leukemia, and lung survivors
This study looks at how an exercise program affects fitness and lung function in young people who are survivors of certain conditions (heart transplant, leukemia, or lung disease from prematurity). The goal is to see whether exercise can improve breathing and overall physical function safely.
Minneapolis, MinnesotaAges 8–25 - NCT03312686Recruiting
Proton pump medicine effect on esophagus in eosinophilia
This pilot study looks at how proton pump inhibitor medicines (acid reducers) change the flexibility of the esophagus in people who have eosinophilia on esophagus biopsy. It may help doctors understand whether acid control could improve esophagus function in this condition.
Indianapolis, IndianaAges 18–65 - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT05792007Recruiting
Study of bone marrow environment in childhood leukemia
This study looks at what the bone marrow “microenvironment” is like in children newly diagnosed with acute leukemia, to better understand the disease. It also compares leukemia samples to samples from children having certain orthopedic surgery.
ToursAges 1–15 - NCT04855825Recruiting
Wearable robotic exoskeleton to improve walking and thinking in MS
This study tests a wearable robotic exoskeleton to help people with multiple sclerosis walk better and improve thinking/problem-solving. You would use the device during supervised sessions and take brief thinking and movement checks to see if it’s safe and helpful for you.
West Orange, New JerseyAges 18–75 - NCT05136976RecruitingPhase 3
Rituximab for anti-MAG neuropathy in specific patients
This Phase 3 study tests rituximab, an antibody medicine, for people with a particular type of nerve damage called anti-MAG–related demyelinating polyneuropathy. It aims to see if rituximab improves symptoms or function in patients who are considered “good responders.”
BrestAges 18 years+ - NCT05361980Recruiting
Study of safety and results of a pediatric bone implant
This study looks at whether a specific pediatric bone implant is safe and works well for children who need it. By joining, you help researchers track outcomes over time and understand possible implant-related side effects.
Vancouver, British ColumbiaAges birth–25 years - NCT05770037RecruitingPhase 2/Phase 3
Alectinib for ALK-positive cancers in teens and adults
This study tests whether alectinib can treat ALK-positive cancers in adults, teenagers, and children. It focuses on people whose cancer testing shows an ALK change, and who can start oral treatment and have a new tissue sample.
BelfastAges Any age - NCT05768178RecruitingPhase 2/Phase 3
Vemurafenib plus cobimetinib for BRAF-mutant cancers
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
BelfastAges 18 years+ - NCT05770544RecruitingPhase 2/Phase 3
Entrectinib for ROS1 fusion cancers with matching gene test
This trial studies entrectinib, a targeted pill, in people whose cancer has a specific gene change called ROS1 fusion. It may help by shrinking tumors that depend on this ROS1 gene switch, and the study requires starting with a new tissue sample and treatment monitoring.
BelfastAges Any age - NCT05770102RecruitingPhase 2/Phase 3
Atezolizumab for cancers with high mutation or immune markers
This trial tests atezolizumab, a cancer immunotherapy, for people whose tumors have high mutation levels (TMB), or are “MSI-high,” or have CMMRD. It may help shrink cancer or slow its growth by boosting the immune system’s ability to recognize the tumor.
BelfastAges Any age - NCT05886036RecruitingPhase 2
Comparing rituximab vs mosunetuzumab for NLPHL
This trial compares two immunotherapy drugs, rituximab and mosunetuzumab, to see which works better for people with nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) who need treatment. It's for both newly diagnosed and previously treated patients.
Duarte, CaliforniaAges 18 years+ - NCT05907759RecruitingPhase 2
Daratumumab for HIV-related lymphomas and Castleman disease
This trial tests a drug called daratumumab for people with certain HIV-related blood cancers (primary effusion lymphoma, plasmablastic lymphoma) or a related condition called multicentric Castleman disease that has come back or not improved after standard treatment. The drug targets a protein on cancer cells to help the immune system attack them. It might be a new option when standard chemotherapy isn't working or isn't suitable.
Bethesda, MarylandAges 18–120 - NCT05908708Recruiting
Testing a closed-loop insulin system for kids with type 1 diabetes
This trial studies how the Medtronic 780G “closed-loop” insulin system works for young people with type 1 diabetes. It may help by improving how automatically insulin is delivered, depending on your body’s needs.
Ramat Gan, Please SelectAges 1–21 - NCT05891821RecruitingPhase 2
Balstilimab for relapsed lymphoma after standard treatments failed
This phase 2 study tests balstilimab to see if it can be safe and effective for certain lymphomas that came back or didn’t respond to standard treatment. If you qualify, you’ll be checked closely for side effects and how well your lymphoma responds.
YerevanAges 18 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT05898477Recruiting
Studying treatment responses in lymphoma-related HLH
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Birmingham, AlabamaAges Any age - NCT05892393RecruitingPhase 1
Scan test to find CD46-positive multiple myeloma lesions
This Phase 1 study tests a new special scan marker (a radioactive imaging agent) to see whether it can detect certain multiple myeloma spots in the body. If it works, it may help doctors better locate disease using a PET-style scan.
San Francisco, CaliforniaAges 18 years+ - NCT05909059RecruitingPhase 2
CAR-T therapy for people with kidney function problems
This study tests a type of immune treatment (CAR-T) in people whose kidneys are not working well, using chemotherapy first to help the CAR-T work. It may help people with certain blood cancers who have reduced kidney function to still receive CAR-T therapy safely.
Atlanta, GeorgiaAges 18 years+ - NCT05898308RecruitingPhase 4
Test a personalized maintenance plan for pemphigus
This study compares a tailored “maintenance” treatment plan to the usual standard care in adults with newly diagnosed pemphigus (PV or PF). It aims to see whether the personalized approach can help control the disease while reducing the burden of long-term treatment.
AmiensAges 18–80
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,241 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.